Core Viewpoint - The article discusses the escalating conflict between two major players in the biocosmetics industry, Huaxi Biological and Juzhi Biological, triggered by a dispute over product testing results and allegations of misleading information [2][5][10]. Group 1: Company Statements and Actions - On June 1, Huaxi Biological issued a statement supporting Dr. Hao Yu in maintaining consumer rights and announced the initiation of a third-party retesting process [2]. - Juzhi Biological responded swiftly, revealing that they had received an apology from the testing agency used by Dr. Hao, claiming that the agency had not authorized him to use the testing report [5]. - Dr. Hao later reported difficulties in contacting the testing agency, leading to a stalemate in the dispute [7][9]. Group 2: Regulatory and Market Reactions - The conflict has drawn regulatory attention, with Huaxi Biological reporting misleading research reports to the China Securities Regulatory Commission [9]. - Huaxi Biological's revenue for 2023 is projected to decline by 4.45% to 6.076 billion yuan, with a significant drop in net profit by 42.44% to 490 million yuan [14]. - Juzhi Biological, on the other hand, has seen substantial growth, with revenue increasing from 2.36 billion yuan in 2022 to 5.539 billion yuan in 2024, reflecting an average annual growth rate of nearly 50% [15]. Group 3: Industry Dynamics and Trends - The article highlights a shift in consumer demand from hyaluronic acid to recombinant collagen, indicating a fundamental change in industry competition [18]. - The cost of producing hyaluronic acid has significantly decreased due to technological advancements, leading to a reduction in profit margins and the erosion of traditional market barriers [18][19]. - New entrants in the market, such as Meiliu Biotechnology, are further driving down costs, potentially disrupting the high-price structure of the recombinant collagen market [19][20].

Core Viewpoint - The controversy surrounding the skincare brand "可复美" has led to a significant decline in the stock price of its parent company, 巨子生物, which has dropped 23% in just 10 trading days, resulting in a market value loss of over 21.2 billion HKD [2]. Group 1: Company Response and Actions - 巨子生物 announced on May 24 that it had commissioned multiple authoritative third-party testing agencies to verify the collagen content in its "重组胶原蛋白" products, but has yet to release the results [2]. - The company's IR department stated that the testing process is ongoing and results will be reported to the public as soon as they are available [2]. Group 2: Market and Competitive Dynamics - The controversy began when beauty blogger "大嘴博士" publicly questioned the actual collagen content in 可复美's core product, revealing it to be only 0.0177%, which contradicted the product's marketing claims [3]. - 巨子生物 responded to the allegations by asserting that the claims were "seriously inaccurate" and released self-test results showing collagen content exceeding 0.1% [3]. - The situation has been complicated by the involvement of competitor 华熙生物, which publicly supported the claims made by 大嘴博士, indicating a long-standing rivalry between the two companies [4]. - 华熙生物 has faced pressure in the market as its core product, "玻尿酸," has seen declining interest, while 巨子生物's "重组胶原蛋白" products have gained popularity, contributing to its rapid growth in both performance and market valuation [4].

Core Viewpoint - The article discusses the rise and subsequent challenges faced by Juzi Biotechnology, highlighting its rapid growth in the beauty industry and the controversies surrounding its flagship product, the collagen stick, amid accusations of ingredient falsification [4][11][12]. Company Overview - Juzi Biotechnology, founded by Yan Jianya and Fan Daidi, has become a significant player in the beauty industry, particularly known for its "recombinant collagen" technology [10][11]. - The company achieved a market value of over 450 billion yuan in May, making its founders the richest in Shaanxi province [4]. - Juzi Biotechnology's net profit increased from 1 billion yuan in 2022 to 2.06 billion yuan in 2024, with a peak gross margin of 82% [11][21]. Recent Controversies - In May, Juzi Biotechnology faced backlash from Huaxi Biotechnology, which accused it of misleading marketing regarding the safety and efficacy of its products [6][19]. - Influencer "Big Mouth Doctor" Hao Yu claimed that the collagen stick contained only 0.0177% of the advertised recombinant collagen, significantly below the stated minimum of 0.1% [13][17]. - Juzi Biotechnology's response included a denial of the allegations and a commitment to legal action against misinformation campaigns [7][15]. Market Impact - Following the allegations, Juzi Biotechnology's stock price dropped over 8%, reducing its market capitalization from 909 billion HKD to 735 billion HKD within ten days [7][11]. - The controversy has affected not only Juzi Biotechnology but also other companies in the recombinant collagen sector, leading to a decline in their stock prices [7][11]. Competitive Landscape - The article highlights the competitive tension between Juzi Biotechnology and Huaxi Biotechnology, with both companies investing heavily in marketing and facing scrutiny over their product claims [21]. - Juzi Biotechnology's marketing expenses exceeded 2 billion yuan in 2024, while Huaxi Biotechnology's marketing costs were reported at 2.464 billion yuan [21].

Core Viewpoint - The conflict between Huaxi Biological and Juzi Biological has escalated into a public confrontation over product integrity and industry standards, with both companies making serious allegations against each other regarding the authenticity of their products and testing methods [1][3][16]. Group 1: Company Actions and Statements - Huaxi Biological announced a capital relationship with Dr. Hao Yu, holding 32.4% of the shares in his company, and positioned it as an important member of the "Huaxi ecosystem," promising technical support and personal protection [1][6]. - Huaxi's statement accused Juzi Biological of manipulating public opinion and demanded that they address product integrity issues, threatening to disclose third-party testing evidence if they do not comply [1][7]. - Juzi Biological quickly countered by claiming that the testing agency used by Dr. Hao had not authorized him to use their report and accused Huaxi of maliciously distorting facts [9][12]. Group 2: Market Reactions and Financial Implications - Following the public dispute, Juzi Biological's stock price fell over 4.69%, while Huaxi Biological's stock rose by 6.94%, indicating market concerns about Juzi's upcoming performance during the critical "618" shopping festival [2][12]. - Juzi's flagship product, "Collagen Stick," is projected to generate 3.6 billion yuan in revenue in 2024, raising concerns about the impact of the ongoing controversy on consumer trust and potential sales [2][14]. - In contrast, Huaxi Biological reported a revenue decline of 11.61% year-on-year for 2024, with a net profit drop of 70.59%, highlighting the financial pressures both companies are facing [15]. Group 3: Industry Context and Future Outlook - The dispute reflects a broader competition between two technological routes in the medical beauty industry: the hyaluronic acid camp represented by Huaxi Biological and the recombinant collagen camp represented by Juzi Biological [14][16]. - The market for collagen-based skincare products is expected to surpass that of hyaluronic acid by 2026, with a compound annual growth rate of 52.6%, attracting numerous companies to enter the sector [14]. - The ongoing conflict may lead to increased scrutiny from regulatory bodies, as the lack of clear testing standards for recombinant collagen has resulted in divergent claims from both companies [9][11].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 86 HKD, based on absolute and relative valuation results [4][14][6]. Core Insights - The company, Shumei Co., Ltd. (2145.HK), is a multi-brand cosmetics group that has shown remarkable growth, particularly through its main brand, KANS, which has become the second-largest domestic beauty brand in terms of online GMV by 2024 [2][23]. - The company has capitalized on the growth of the Douyin platform, leading to a significant increase in revenue and net profit from 2022 to 2024, with projected compound annual growth rates of 59.3% and 130.5%, respectively [2][4]. - The cosmetics industry in China is experiencing both growth and competition, with opportunities in lower-tier markets and niche segments, particularly in color cosmetics and infant care [3][72]. Company Overview - Shumei Co., Ltd. was established in 2004 and went public in 2022, offering a wide range of products including skincare, maternal and infant care, personal care, and makeup [2][23]. - The main brand, KANS, has been a significant contributor to the company's revenue, accounting for 82.3% of total revenue in 2024, with a projected revenue of 55.91 billion CNY [25][23]. Financial Performance - The company achieved a revenue of 67.93 billion CNY in 2024, representing a year-on-year growth of 62.1%, and a net profit of 7.81 billion CNY, up 69.4% from the previous year [4][5]. - The report forecasts net profits for 2025, 2026, and 2027 to be 10.6 billion CNY, 13.8 billion CNY, and 17.4 billion CNY, respectively, with corresponding EPS of 2.65, 3.47, and 4.37 CNY [4][14]. Industry Analysis - The Chinese cosmetics industry is projected to reach a scale of 537.2 billion CNY in 2024, with a slight decline of 2.0% year-on-year, indicating a shift in consumer preference towards cost-effective products [3][72]. - The competitive landscape is characterized by domestic brands leveraging online channels, with Douyin emerging as a key platform for growth [3][72]. Growth Drivers - The main brand KANS is expected to continue its growth trajectory through product innovation and channel diversification, while the emerging brand Yipai is anticipated to achieve triple-digit growth in revenue for 2023 and 2024 [4][10]. - The company is also exploring new brands and product lines, such as the hair care brand Jifang and the makeup brand NAN beauty, to create multiple growth avenues [4][12].

Core Viewpoint - The cosmetics retail sales in China for January to April 2025 showed a year-on-year increase of 4%, underperforming the overall retail market by 0.7 percentage points, but this represents an improvement compared to 2024. The industry is characterized by four key trends: innovation in personal care products, breakthroughs in ingredient technology, rising emotional consumption, and the continuation of affordable consumption [1][3]. Investment Recommendations - The company recommends increasing holdings in the personal care sector, highlighting quality companies that benefit from product innovation and opportunities in Douyin channels, with key recommendations including Ruoyuchen (003010), Dengkang Oral (001328), and Runben Co. [2] - In the beauty sector, structural opportunities are identified, with key recommendations for companies like Jinbo Biological, Juzi Biological, and Marubi Co. that are positioned to benefit from the collagen restructuring trend. Additionally, brands like Maogeping, Shumei Co., Proya (603605), and Shanghai Jahwa (600315) are expected to gain from the overall increase in domestic market share [2]. - Companies expected to bottom out and potentially see a turning point include Lafang Household (603630), Shuiyang Co. (300740), Betaini (300957), Furuida (600223), Huaxi Biological, Fulejia (301371), Meilitiantian Medical Health, and Qingsong Co. (300132) [2]. Industry Overview - Demand remains stable, with the rise of domestic brands in the beauty and personal care sectors accelerating. The cosmetics retail sales for January to April 2025 increased by 4% year-on-year, which is a 0.7 percentage point underperformance compared to the overall retail market, but shows improvement from 2024. The overall demand is stable, with leading domestic brands performing well and the rise of new domestic brands spreading from beauty to personal care categories [3][4]. Trends - The industry is witnessing several trends: 1) Personal care transformation with new products in traditional categories, supported by content e-commerce creating a favorable environment for new product launches [4]. 2) Ingredient innovation, particularly in collagen restructuring, with various types and structural innovations expanding application scenarios [4]. 3) Emotional consumption, where cultural, stylistic, and experiential demands are driving the growth of domestic trends in cosmetics and fragrances [4]. 4) Affordable consumption, where the trend for cost-effectiveness continues under supply-demand resonance, benefiting strong supply chains and well-operated brands [4]. Key Companies - Looking ahead to 2025, the market risk appetite is expected to recover significantly. The beauty sector is characterized by substantial changes and a clear trend of rising domestic brands, indicating strong growth potential and leadership in new consumption [5]. The differentiation among brands is increasing, emphasizing the selection of high-growth targets driven by product innovation and attention to marginal improvements [5].

Group 1 - The U.S. has announced an increase in tariffs on imported steel and aluminum from 25% to 50%, causing a strong global reaction and leading to a drop in steel stocks in Asia [2] - South Korea's trade ministry held an emergency meeting with industry leaders to discuss the potential impact of these tariffs on steel exports, which accounted for 13.1% of South Korea's total steel exports in 2024 [2] - Major steel trading partners of the U.S., including Canada and the EU, condemned the tariff increase and warned of possible retaliatory measures [2] Group 2 - In June, brokerage firms have released their "golden stocks," with over a hundred stocks recommended, particularly in the machinery and pharmaceutical sectors [3] - The machinery sector is optimistic about investment opportunities arising from the development of controlled nuclear fusion, while the pharmaceutical sector suggests focusing on CXO, specialty raw materials, and pharmacies [3] Group 3 - The second round of negotiations between Russia and Ukraine concluded with an agreement to exchange the remains of fallen soldiers and a new round of prisoner swaps [4] - Russia plans to unilaterally transfer 6,000 fallen soldiers' remains to Ukraine next week, and both sides will establish a medical committee for regular exchanges of severely injured soldiers [4] Group 4 - A surge in interest around "stablecoins" has led to numerous broker calls focusing on this topic, with several stablecoin-related stocks showing strong performance [5] - Despite the potential applications of stablecoins, there are concerns about market speculation and a lack of in-depth research from major institutions [5] Group 5 - Insurance companies have been actively increasing their stakes in high-dividend assets, particularly bank stocks, with 15 instances of stake increases reported by seven insurance firms by the end of May [6] - The current wave of stake increases is driven by the need for stable cash returns in a low-interest-rate environment [6] Group 6 - An announcement from the White House indicated that the U.S. and China are expected to hold talks regarding tariff issues [7] - The U.S. International Trade Court has blocked a tariff policy announced by Trump, stating that such powers belong exclusively to Congress [7] Group 7 - An announcement from Annier indicated that the company is planning a change in control, with the current major shareholders proposing to transfer 13.03% of their shares to a counterparty [8][17] - The stock of Annier will be suspended from trading starting June 3, with the suspension expected to last no more than two trading days [8][17] Group 8 - BYD reported a total of 382,500 new energy vehicle sales in May 2025, with overseas sales accounting for 89,000 units [28] - BAIC BluePark's subsidiary saw a 215.11% year-on-year increase in sales in May 2025, totaling 17,100 units [29] - Great Wall Motors reported May sales of 102,200 vehicles, marking an 11.78% year-on-year increase, with 32,600 of those being new energy vehicles [30]

丨 2025年6月3日 星期二 丨 NO.1 华熙生物、巨子生物舆论风波升级，美妆博主回应：不认可巨子生物的说法 每经记者｜甄素静 每经编辑｜董兴生 近日，浙江海圣医疗器械股份有限公司IPO申请获北交所受理，中信证券担任保荐机构。招股书显示， 海圣医疗专注于麻醉、监护类医疗器械的研发、生产和销售，产品广泛应用于麻醉科、ICU等临床科 室。 点评：海圣医疗冲刺北交所IPO，专注于麻醉监护器械研发等，产品应用于多临床科室，若成功上市， 或将借助资本加速技术创新与市场拓展。 NO.4 和美药业递表港交所 据港交所5月29日披露，赣州和美药业股份有限公司向港交所主板递交上市申请。和美药业于2002年成 立，截至2025年5月21日，和美药业已开发7个小分子候选药物，针对具有高度未满足需求的自身免疫和 肿瘤疾病。其中4种候选药物处于II期、III期临床试验或NDA阶段，适用于12种适应证。 6月1日晚，华熙生物在微信公众号发表长文支持"大嘴博士"（郝宇）。当日深夜，巨子生物在微信公众 号发布了一份声明，称有关"可复美"未添加重组胶原蛋白的争议，5月30日公司收到了来自"大嘴博 士"所用检测机构的道歉声明，并贴出了检验机 ...

Core Viewpoint - The ongoing public dispute between Huaxi Biological and Juzhi Biological highlights the competitive tension in the aesthetic medicine industry, particularly regarding hyaluronic acid and recombinant collagen products [3][10]. Group 1: Company Statements - Huaxi Biological issued a statement on June 1, 2023, supporting beauty blogger Dr. Hao Yu, criticizing an unnamed company for using "internet water army" tactics and threatening to disclose testing results if issues are not addressed [3][4]. - Juzhi Biological responded later that day, accepting an apology from the testing agency used by Dr. Hao Yu but asserting that they would pursue legal action against those spreading false information [3][8]. - Dr. Hao Yu contested Juzhi Biological's claims, stating that the testing agency's statement did not include an apology and questioned why Juzhi had not released its own testing results after ten days [9][10]. Group 2: Market Dynamics - The dispute is rooted in a broader competition for market share between hyaluronic acid and recombinant collagen, with Huaxi Biological's performance declining alongside the perception of hyaluronic acid as "outdated" [10]. - Huaxi Biological's revenue from functional skincare products, which include recombinant collagen, has seen significant declines of 18.45% and 31.62% in 2023 and 2024, respectively, while Juzhi Biological's "Kefumei" brand has shown strong growth with revenues of 27.88 billion and 45.4 billion in the same years [11]. - The pricing landscape for aesthetic products indicates that domestic hyaluronic acid is positioned at the lower end of the market, with prices ranging from approximately 1,000 to 2,000 yuan per unit, while recombinant collagen is priced higher, around 3,000 yuan [13][14]. Group 3: Industry Trends - The aesthetic medicine market is experiencing a shift with the introduction of new injectable materials, which has led to a decrease in hyaluronic acid's market share from 42% in 2021 to an estimated 36% in 2024 [16]. - The emergence of new materials, such as hydroxyapatite and PDRN solutions, is expected to further challenge the dominance of hyaluronic acid, although its unique properties may still provide competitive advantages [16][17].

Summary of Key Points from Conference Call Records Industry Overview - **Hong Kong Stock Market**: The market shows strong resilience, exceeding expectations, with significant participation from southbound funds and foreign investments in technology, consumer, and pharmaceutical sectors in May 2025 [2][1] - **Chinese Innovative Drug Industry**: Benefiting from national support policies, with a rising demand for Chinese innovative drugs in the US due to the impending patent cliff in the US and Europe. The proportion of Chinese innovative drug projects authorized in the US reached 50% in Q1 2025 [4][1] - **Domestic IP Market**: Rapid growth observed, with VRA transaction volume on platforms like Xianyu increasing by 105% year-on-year in Q1 2025. Chinese companies excel in supply chain management and e-commerce innovations [11][1] - **Bubble Mart's Overseas Business**: Continued unexpected growth, with overseas revenue projected to reach 10 billion yuan in 2025, marking a 100% increase from the previous year [12][1] Core Insights and Arguments - **Performance of Hong Kong Stocks**: Companies like Hengke have shown significant profit improvements, and the overall earnings elasticity is better than expected, indicating a favorable outlook for 2025 [2][1] - **Innovative Drug Development**: China has become the largest country for innovative drug pipelines globally as of 2024, showcasing advantages in technology and research cycles [5][1] - **Market Demand for Innovative Drugs**: The innovative drug sector is less affected by tariffs due to its reliance on rights authorization rather than physical goods trade [3][1] - **Emerging Trends in Consumer Spending**: The rise in per capita GDP has led to increased demand for creative and culturally valuable products, driving growth in the IP derivatives sector [10][1] Additional Important Content - **Investment Opportunities in New Consumption**: The new consumption sector is characterized by strong alpha candidates, particularly in beauty care and gold jewelry, with companies like Laopu Gold showing significant growth potential [13][1][18][1] - **Automotive Industry Trends**: The demand for new vehicles remains strong, with brands like BYD, Geely, and Xpeng showing potential for growth. The commercial vehicle market is also recovering, with companies like Heavy Truck and Weichai being highlighted [22][1][24][1] - **Financial Performance of Gold Jewelry Sector**: The gold jewelry sector is experiencing a product power renaissance, with companies that have strong design capabilities and brand positioning benefiting from market share growth [16][1][17][1] - **HHR Company Outlook**: HHR is expected to see a turnaround in revenue and profit, with a projected net profit of 640-650 million yuan in 2025, indicating significant improvement potential [26][1]